anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Combat casualty care can be complicated by transport times exceeding the "golden hour," with intervention and resuscitation limited to what the medic can carry. Pharmaceutical albumin comes highly saturated with nonesterified fatty acids (NEFAs). We recently showed that treatment with 25% bovine serum albumin (BSA) loaded with oleic acid, but not NEFA-free BSA, improved survival for hours after severe hemorrhage and often eliminated the need for resuscitation in rats. However, it was unknown whether pharmaceutical albumin, derived from human sources and loaded with caprylic acid (CA), would have the same benefits. We compared adjunct treatment with oleic acid-saturated BSA, CA-saturated BSA, pharmaceutical human serum albumin, or a no-albumin control in a similar rat hemorrhagic shock model to determine whether the three NEFA-albumin groups provided the same benefits relative to control. We found almost no significant differences among the NEFA-albumin groups in any measure. Mortality in controls was too low to allow for detection of improvement in survival, but NEFA-albumin groups had significantly improved hemodynamics, lactate clearance, and greatly reduced fluid requirements compared with controls. Contrary to expectations of "dehydration," 25% albumins shifted little additional fluid into the vasculature. Rather, they restored protein to the autotransfusion fluid. Nonesterified fatty acids-albumin did not worsen lung permeability, but we observed a loss of circulating protein suggesting it may have increased overall vascular permeability. Our findings suggest that, though imperfect, 25% human serum albumin could be a solution for resuscitation in austere conditions requiring prolonged field care.
<P>PROBLEM TO BE SOLVED: To obtain a composition for the oral cavity, which is highly safe and effectively prevents or ameliorates a foul breath.  <P>SOLUTION: The composition for the oral cavity comprises an extract extracted from a roasted material prepared by roasting bran obtained from seeds of at least one kind of plant. The bran is rice bran. The amount of the extract extracted from the roasted material mixed is 0.1-20 wt.%. The composition comprises a propolis extract besides the extract extracted from the roasted material. The amount of the propolis extract mixed is 0.1-20 wt.%. The composition comprises a crude medicine having hemostatic and/or antiphlogistic and anti-inflammatory effect, its extract or processed material.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Drowsiness occurs in over 20% of patients treated with doxepin hydrochloride cream, especially in patients receiving treatment to greater than 10% of their body surface area. Patients should be warned about the possibility of sedation and cautioned against driving a motor vehicle or operating hazardous machinery while being treated with doxepin hydrochloride cream.

The sedating effects of alcoholic beverages, antihistamines, and other CNS depressants may be potentiated when doxepin hydrochloride cream is used.

If excessive drowsiness occurs it may be necessary to reduce the frequency of applications, the amount of cream applied, and/or the percentage of body surface area treated, or discontinue the drug. However, the efficacy with reduced frequency of applications has not been established. Keep this product away from the eyes.
PURPOSE:To obtain an essentially non-toxic immuno-enhancing agent administrable at a high dose without causing side effects by using squeezed juice of premature green leaves of wheat as an active component. CONSTITUTION:Green leaves of what in premature stage, preferably stalk and leaf of wheat of a period from the tiller-starting stage to the full heading time are squeezed preferably by mechanical means without applying excessive thermal denaturation and coarse solid materials are removed from the juice. The obtained green juice is centrifuged and the supernatant liquid is disinfected and filtered to obtain a squeezed juice component. The green juice may be used as the squeezed juice component as it is. The squeezed juice component can be administered as it is, however, it is preferably spray-dried or freeze-dried and the obtained powder, its solution or an extract is used as the objective agent. The daily does of the active component is 0.1-5 mg, preferably 0.5-2 mg per 1 kg of body weight.
This prospective study will include 50 patients under the age of 18 years who are having laparoscopic pyloromyotomy. There will be no change in the anesthetic or perioperative care of these patients. Tissue and cerebral oxygenation will be monitored using near infrared spectroscopy (NIRS). Prior to anesthetic induction, the NIRS monitor will be placed on the forehead. The device is non-invasive like pulse oximetry using a non-painful adhesive sticker. The device can be applied to different sites on the body to measure cerebral, tissue or even organ oxygenation. For the purpose of the study, the investigators will place one monitor on the forehead to measure tissue oxygenation and a second over the lower back to measure tissue (muscle or renal) oxygenation. These devices are used routinely in the operating room and the cardiothoracic intensive care unit for cardiac patients. Although not used on every surgical procedure, NIRS monitoring can be used on all patients who are undergoing major surgical procedures. Tissue and cerebral oxygenation will be recorded continuously starting just prior to anesthetic induction until the completion of the procedure.
The present invention relates to a method and pharmaceutical composition for a combination of pregabalin-etoricoxib for the treatment of pain. The process is obtained by two actives consisting of surfactant dispersion in a solvent, thereby adding etoricoxib in a mixer with one or more diluting, binding, and disintegrating agents. The obtained powder mixture is granulated, dried in a fluidized bed or fixed bed oven, and screened in a stainless steel mesh or plate. Then, the dry bound powder is added and sieved in a mixer, thereby mixing with one or more lubricious, slip and/or antistick agents. At the same time, pregabalin is mixed with and one or more diluting and disintegrating agents. Also are mixed the blended powders with one or more lubricious, slip and/or antistick agents. Finally, in a capsule equipped with a double hopper, each capsula is filled with the equivalent powder at a final etoricoxib concentration of up 10mg to 150mg and with the powder pregabalin mixture equivalent at a final concentration of up 25mg to 300mg.
HIV infected individuals are at increased risk for developing atherosclerosis, which is a build-up of plaque within the arteries and which may lead to various forms of heart disease. It is unknown, however, why individuals with HIV are more susceptible to heart disease compared to others. Atherosclerosis may develop more rapidly due to HIV infection, the use of antiretroviral medications, or a combination of the two. HIV lipodystrophy syndrome, in which body fat distribution is altered, may also be a risk factor. If heart disease is not properly treated, individuals place themselves at risk for heart attacks, strokes, or organ failure. In previous studies involving HIV and heart disease, women have been under-represented. This study will examine a group of women participating in the Women's Interagency HIV Study (WIHS), which is examining the impact of HIV infection and its clinical, laboratory, and psychosocial effects in women. By using ultrasound imaging, the progression of subclinical atherosclerosis will be assessed. WIHS study data will then be used to examine possible relationships between atherosclerosis and factors associated with HIV infection in women. The results of this study will have major implications for the development of strategies to predict, prevent, or reverse atherosclerosis and heart disease in HIV infected individuals.

This 4-year study will enroll 750 HIV infected women and 250 HIV uninfected women who are participating in the WIHS study. Participants will undergo an initial ultrasound imaging of the neck to measure the size and thickness of the arteries. They will return for a repeat ultrasound at Years 2, 3, and 4 to assess any progression of atherosclerosis. Data from the participants' biannual WIHS study visits, including HIV medication usage, viral load and CD4 test results, and occurrence of AIDS and other illnesses, will be reviewed. Results of participant's inflammation marker tests, which may indicate the presence of atherosclerosis, including white blood cell count, C-reactive protein, E-selectin, and intercellular adhesion molecule 1, will also be reviewed.
The invention provides a foot tub special for a diabetic patient. The foot tub comprises an outer tub and an inner tub. The inner tub is arranged inside the outer tub through a spiral height adjusting mechanism. A vibration spring is arranged between tub bottoms of the outer tub and the inner tub. A vibration original piece is arranged at the bottom of the outer side of the inner tub. A stretchable strut is installed on the outer side wall of the outer tub. A magnifying lens is arranged on a handheld handle of the stretchable strut. A sponge tip is arranged at the tail end of the stretchable strut. The two outer side walls of the outer tub are provided with inspectoscopes in a hinged mode. Supporting feet are fixedly installed below the inspectoscopes. A water thermometer is arranged on the inner side wall of the inner tub. A temperature alarm device is arranged between the outer tub and the inner tub and connected with the water thermometer. The foot phenomenon can be conveniently inspected during a foot bath of the patient, the inducements such as the water temperature of the foot bath, the foot soaking time and scrubbing with strength which are likely to damage the feet of the diabetic patient are limited, diabetic feet can be prevented and found easily while the diabetic patient has a comfort foot bath, traditional Chinese medicine compositions are combined, the treatment effect reaches 95%, and the foot tub is safe, comfortable and quite good in effect.
A 33-year-old man was diagnosed with acute myeloid leukemia (AML). He was treated with daunorubicin and cytarabine and achieved complete remission. He underwent consolidation therapy with three cycles of venetoclax and azacitidine (VEN+AZA). He received cord blood transplantation following a reduced-intensity conditioning (RIC) regimen. After 19 months, an extramedullary mass appeared in the paranasal sinuses along with vision loss, and relapsed AML was diagnosed based on a biopsy. Palliative irradiation was performed because the patient did not wish to receive a second transplantation. A painful extramedullary mass was found in the inguinal area, and radiation therapy was performed. Subsequently, extramedullary masses appeared in the submandibular region, but radiation therapy was not feasible because the irradiation field overlapped with that of the previous therapy. The extramedullary masses decreased after two cycles of VEN+AZA therapy. This is a rare report of VEN+AZA therapy for an extramedullary relapse of AML.
A method of treating dry eye or dry eye symptom includes topically administering a formulation to the eye. The formulation includes an ophthalmically acceptable carrier and a pharmaceutically effective amount of a positive modulator of PSA-NCAM. The administered formulation treats dry eye or dry eye symptoms. A method of stimulating the expression of PSA-NCAM in neural beds of an eye includes topically administering a formulation to the eye. The formulation includes an ophthalmically acceptable carrier and a pharmaceutically effective amount of a positive modulator of PSA-NCAM. The administered formulation may stimulate the expression of PSA-NCAM in the neural beds of the eye. A formulation includes an ophthalmically acceptable carrier and a therapeutically effective amount of a positive modulator of polysialic acid-neural cell adhesion molecule (PSA-NCAM).
Serious, life-threatening, or fatal respiratory depression has been reported with the use of opioids, even when used as recommended. Respiratory depression, if not immediately recognized and treated, may lead to respiratory arrest and death. Management of respiratory depression may include close observation, supportive measures, and use of opioid antagonists, depending on the patient's clinical status [see OVERDOSAGE]. Carbon dioxide (CO2) retention from opioid-induced respiratory depression can exacerbate the sedating effects of opioids.

While serious, life-threatening, or fatal respiratory depression can occur at any time during the use of Pentazocine and Naloxone Tablets, the risk is greatest during the initiation of therapy or following a dosage increase. 

To reduce the risk of respiratory depression, proper dosing and titration of Pentazocine and Naloxone Tablets are essential [see DOSAGE AND ADMINISTRATION]. Overestimating the Pentazocine and Naloxone Tablets dosage when converting patients from another opioid product can result in a fatal overdose with the first dose.

Accidental ingestion of even one dose of Pentazocine and Naloxone Tablets, especially by children, can result in respiratory depression and death due to an overdose of pentazocine.

Educate patients and caregivers on how to recognize respiratory depression and emphasize the importance of calling 911 or getting emergency medical help right away in the event of a known or suspected overdose [see PRECAUTIONS, Information for Patients].
Lung adenocarcinoma (LUAD) remains a leading cause of cancer-related mortality worldwide. Understanding the dysregulated epigenetics governing LUAD progression is pivotal for identifying therapeutic targets. CBX4, a chromobox protein, is reported to be upregulated in LUAD. This study highlights the dual impact of CBX4 on LUAD proliferation and metastasis through a series of rigorous in vitro and in vivo experiments. Further investigation into the underlying mechanism through high-throughput ChIP-seq and RNA-seq reveals that CBX4 functions in promoting LUAD proliferation via upregulating PHGDH expression and subsequent serine biosynthesis, while concurrently suppressing LUAD metastasis by inhibiting ZEB2 transcription. CBX4 facilitates PHGDH transcription through the interaction with GCN5, inducing heightened histone acetylation on the PHGDH promoter. Simultaneously, the inhibition of ZEB2 transcription involves CBX4-mediated recruitment of canonical PRC1 (cPRC1), establishing H2K119ub on the ZEB2 promoter. These findings underscore CBX4's pivotal role as a regulator of LUAD progression, emphasizing its diverse transcriptional regulatory functions contingent upon interactions with specific epigenetic partners. Understanding the nuanced interplay between CBX4 and epigenetic factors sheds light on potential therapeutic avenues in LUAD.
Infants will perform individualized goal-directed activities for 30-45 minutes per day with CT system, while continuing SC. The CT training will be monitored and modified remotely by clinical staff, according to infants' developmental needs, abilities and progresses. It will last 8 wks.
The layered multi-display control scheme may provide various communication control options for the surgeon controlled secondary display and the primary operating room display. The powered surgical tool may be in operative communication with a local display and at least one primary monitor in the operating room outside the sterile field to display a plurality of data and/or imaging sources. The local display may be interacted with by the surgeon inside the sterile field. A display outside the sterile field may display an image of an aspect of the laparoscopic endoscope and may contain superimposed other data streams from other devices outside the endoscope. The secondary display may be used to direct content from its display up onto the primary display or to remove the content from the display. The added or removed data stream may originate from, be passing through, or be networked with the auxiliary display.
BACKGROUND: Cachexia is prevalent in cancer patients. The conventional diagnostic criteria for cachexia are often based on Western evidence, lacking consensus for Asian populations. This study aims to compare Asian Working Group for Cachexia (AWGC) criteria with Fearon's criteria, assessing their differences in population characteristics and prognostic impact.
METHODS: The clinical data of patients who underwent radical gastrectomy between 2013 and 2019 were prospectively collected. Cachexia diagnosis involves the utilization of either AWGC criteria and the previous international consensus proposed by Fearon et al. A scoring model is established based on the optional criteria according to the AWGC criteria. Univariate and multivariate logistic and Cox regression analysis were conducted to determine the independent effect factors for postoperative complications and overall survival.
RESULTS: In a total of 1330 patients, 461 met AWGC cachexia criteria and 311 met Fearon's criteria. Excluding 262 overlapping cases, those diagnosed solely with AWGC-cachexia had higher age and lower BMI, albumin, hemoglobin, and handgrip strength compared to those by Fearon's criteria alone. AWGC-cachexia independently increased the risk of postoperative complications, whereas Fearon's criteria did not. Patients with AWGC-cachexia also exhibited shorter overall survival than Fearon's criteria. The AWGC-based cachexia grading system effectively stratifies the risks of postoperative complications and mortality.
CONCLUSIONS: The AWGC criteria is more effective in diagnosing cancer cachexia in the Asian population and provide better prognostic indicators.
The invention relates to a benzaconine transdermal gel having effects of relieving pain and resisting inflammation. The gel comprises the following components in percentage by weight: 0.1 to 10 percent of benzaconine, 2 to 30 percent of transdermal penetrating agent, 60 to 95 percent of solvent and 1 to 20 percent of gel matrix. The gel is prepared by dissolving the benzoyl aconine transdermal, the transdermal penetrating agent and the solvent in the gel matrix. The benzaconine keeps the biological activities of relieving the pain and resisting the inflammation of aconitine, the toxicity is obviously reduced, medicaments can directly reach lesion sites through transdermal medicament delivery, and the safety is further improved. The benzaconine and the aconitine have basically consistent transdermal penetrating behaviors, can be directly penetrated into skin and have quick response. Animal medicinal effect tests in which the benzaconine is prepared into the gel show that the gel has obvious and exact pharmacological effects of relieving the pain and resisting the inflammation.
Patients were treated with Sacituzumab Govitecan 10 mg/kg in 21-day treatment cycles with intravenous infusions on days 1 and 8 and continued until disease progression or unacceptable toxicity. Radiotherapy was administered after the second infusion of Sacituzumab Govitecan, on day 9 after the start of this regimen. The radiotherapy regimen was: brain metastases at a dose of 60 Gy/20 doses. For lesions located adjacent to the brainstem and optic nerve, 54 Gy/20 doses were given. For patients with ≥5 lesions, whole-brain radiotherapy at 40 Gy/20 doses was synchronized with radiotherapy to localized brain metastases.
Participants with locally advanced or metastatic NSCLC harboring specific EGFR mutations will be administered escalated doses of EGF816 orally once a day as continuous daily dosing in each cycle (of 28 days) during Phase I part of the study. The starting dose for the Phase I part first cohort of patients will be 75 mg once per day capsule.
Intervention: increase and decrease positive end-expiratory pressure. PEEP titration: 20 minutes before the end of anesthesia and surgery PEEP was increased by 2 on every 5 breaths to 11 ventilation was maintained on PEEP 11 for 2 minutes.Then, PEEP was reduced by 2 for every 5 breaths to 5.Total time to titrate was 5 minutes.
Amyloid β (Αβ) aggregates are considered as possible targets for therapy and or diagnosis of Alzheimer disease (AD). It has been previously shown that curcumin targets Αβ plaques and interferes with their formation, suggesting a potential role for prevention or treatment of AD. In the present invention, curcumin-derivatives with improved physicochemical properties were synthesized and a "click chemistry" as well as a conventional liposome preparation method, were used to generate nanoliposomes decorated with the curcumin derivatives. These derivatives were designed to maintain the planar structure required for interaction with Αβ, as directly confirmed by Surface Plasmon Resonance experiments. Surface Plasmon Resonance experiments, measuring the binding of flowing liposomes to immobilized Αβ1-42, indicated that the liposomes exposing curcumin derivatives have extremely high affinity for Αβ1-42 fibrils (1-5 nM), likely because of the occurrence of multivalent interactions. The present invention describes the synthesis of the curcumin derivatives and the preparation and characterization of new nanoliposomes with a very high affinity for Αβ1-42 fibrils, to be exploited as vectors for the targeted delivery of new diagnostic and therapeutic molecules for AD.
(1) An antiseptic composition comprising (a) water; (b) an antibacterial component comprising a phenylalkanol, a phenol substituted with one or more C1-C12 alkyl groups, and a C3-C12 di-ol; and (c) a preservative component comprising one or more isothiazolinone compounds of formula (1), wherein R1 is selected from H and C1-C12 alkyl; R2 and R3 are each independently selected from H, Cl and C1-C12 alkyl; or R2 and R3 are taken together to form a C6 aryl ring, is provided. The one or more isothiazolinone compounds of formula (1) preferably comprises one or more of methylisothiazolinone, methychlorolisothiazolinone, benzisothiazolinone, octylisothiazolinone, dichlorooctylisothiazolinone and butylbenzisothiazolinone, particularly methylisothiazolinone and methychlorolisothiazolinone. The phenylalkanol is preferably phenylpropanol. The phenol substituted with one or more C1-C12 alkyl groups is o-cymen-5-ol. The C3-C12 di-ol is preferably decylene glycol. The composition preferably comprises at least 90 wt% water. The composition preferably further comprises 1.00 to 5.00 wt% of a viscosity increasing agent; 0.10 to 3.00 wt% of a skin conditioning agent; and/or 0.10 to 1.00 wt% of a neutralising agent. Preferably the composition comprises less than 10 wt% ethanol or isopropyl alcohol. The composition is preferably in the form of a hand sanitiser or rinse-off composition. The composition is preferably for use as prophylactic against infection, preferably by Pseudomonas aeruginosa and/or Escherichia coli. Preferably the composition is for use as a prophylactic against pneumonia, septic shock, urinary tract infection, gastrointestinal infection, skin and soft tissue infection, diarrhoea and meningitis.